Summary
This article discusses results from the Phase 2 dose-ranging RE-DEEM Trial, as well as results of a post hoc analysis of data from the RE-LY Trial.
- Cerebrovascular Disease
 - Cerebrovascular Disease Clinical Trials
 - Arrhythmias
 - Myocardial Infarction
 
- © 2009 MD Conference Express
 










